The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis. The main questions it aims to answer are:
* What adverse events occur after the infusion of LB-DTK-CMV?
* What is the duration of efficacy following treatment?
* Is there a clinically significant reduction in CMV viral load in plasma and aqueous humor after the infusion?
* Is there a clinically significant improvement in clinical symptoms after the infusion?
Participants will:
* Receive two infusions of LB-DTK-CMV at 2x10\^7cells/m\^2 at two-week intervals beginning at the baseline visit (Cycle 1).
* Take a three-week resting period following completion of Cycle 1.
* Receive two infusions of LB-DTK-CMV at 2x10\^7cells/m\^2 at two-week intervals beginning three weeks after the last dose of Cycle 1 (Cycle 2).